NCT03855995View on ClinicalTrials.gov

A Study Assessing the Safety, Efficacy, and Impact of GlaxoSmithKline Biologicals' RTS, S/AS01E Malaria Vaccine in Young Children Across Sub-Saharan Africa

Active, not recruitingOBSERVATIONAL
Enrollment

77,969

Participants

Timeline

Start Date

March 21, 2019

Primary Completion Date

August 11, 2025

Study Completion Date

August 11, 2025

Conditions
MalariaMalaria Vaccines
Interventions
PROCEDURE

Whole blood sample

Whole blood samples will be collected from all enrolled children hospitalised and suspected of having an AESI or meningitis.

Trial Locations (6)

40100

GSK Investigational Site, Kisumu

Unknown

GSK Investigational Site, Kintampo

GSK Investigational Site, Navrongo

GSK Investigational Site, Chikwawa

GSK Investigational Site, Mangochi

4 0100

GSK Investigational Site, Kisumu

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03855995 - A Study Assessing the Safety, Efficacy, and Impact of GlaxoSmithKline Biologicals' RTS, S/AS01E Malaria Vaccine in Young Children Across Sub-Saharan Africa | Biotech Hunter | Biotech Hunter